Equibles does not estimate personal net worth.
Get an email with a short summary when Bristol Myers Squibb Co publishes a filing, an earnings call transcript or a press release.
Get BMY alertsThe proxy statement of Bristol Myers Squibb Co reports total compensation of $9,340,352 for Adam Lenkowsky in fiscal 2025, including a base salary of $1,131,731. Adam Lenkowsky has spoken on 2 earnings calls and 1 other investor event across 1 company, most recently for Bristol Myers Squibb Co on October 29, 2026. Bristol Myers Squibb Co is classified in the Drug Manufacturers - General industry within the Healthcare sector. Other leadership on record at Bristol Myers Squibb Co includes Christopher Boerner (CEO, COO and Board Member), Christopher Boerner, Ph.D. (CEO, COO and Board Member), David Elkins (CFO) and 6 others.
“So, Alex, we are excited to have launched Symbexis. It's the first approved cell mod in the market. Now, it's still early in the launch, but our teams are executing well.”
“So we've got very good momentum in our growth portfolios. You saw in Q1, we delivered 12% growth year over year in the growth portfolio. And as you said, it's a very young and diversified portfolio.”
“As relates to Kevantig, we're pleased with the Kevantig launch performance. Our teams are executing well. We're seeing use across multiple tumor types. We're seeing uptake in our monotherapy indications as well as in combination treatment, so in RCC, in gastric cancer, and in melanoma.”
Proxy statement
Start not stated–present
Last confirmed March 25, 2026
Drug Manufacturers - General · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Bristol Myers Squibb Co (BMY) | EVP, Chief Commercialization Officer | $1,131,731 | $9,340,352 |
